Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Biodesix ( (BDSX) ) is now available.
On September 11, 2025, Biodesix, Inc. announced a one-for-twenty reverse stock split of its common stock, effective September 15, 2025. This move, approved by stockholders in May 2025, will reduce the number of outstanding shares from approximately 156 million to 8 million, while maintaining the same percentage ownership for stockholders, except for fractional shares which will be compensated in cash. The reverse stock split will also adjust the number of shares and exercise prices for the company’s outstanding equity awards and warrants, aiming to enhance the company’s stock market positioning.
The most recent analyst rating on (BDSX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Biodesix stock, see the BDSX Stock Forecast page.
Spark’s Take on BDSX Stock
According to Spark, TipRanks’ AI Analyst, BDSX is a Neutral.
Biodesix’s stock score is primarily impacted by its financial instability, characterized by high leverage and ongoing losses. While there is some positive momentum in technical indicators and revenue growth, these are overshadowed by the company’s profitability challenges and negative valuation metrics. The earnings call provided some optimism with future guidance, but current financial conditions remain a significant concern.
To see Spark’s full report on BDSX stock, click here.
More about Biodesix
Biodesix, Inc. is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients. The company offers diagnostic tests such as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, which support clinical decisions for personalized care in lung disease. Biodesix also provides development services to biopharmaceutical, life sciences, and research institutions, aiding in the development of diagnostic tests, tools, and therapeutics.
Average Trading Volume: 2,441,192
Technical Sentiment Signal: Sell
Current Market Cap: $76.48M
Find detailed analytics on BDSX stock on TipRanks’ Stock Analysis page.